Smith & Nephew scores 51/100 (Making progress) on SINK's independent climate assessment — scored from public data only, no company payment can change a number. Last verified August 2026.
That places Smith & Nephew joint 75th of 591 companies scored, and 2nd of 12 in Healthcare / Pharmaceuticals.
Smith & Nephew has reduced operational emissions 63% since 2019 and measures Scope 3 across 14 categories, but supply-chain verification remains limited and water management is admittedly not strategic. Nature risk and circular economy depth are absent. Targets exist but lack SBTi validation.
This score is built from public data only. If your practice is stronger than your disclosure, submit evidence for review — or challenge any question, free.
Same formula for every company. No curve. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × ScaleStrongest on Carbon Footprint — Operations and Controversies & Red Flags (8/10, 8/10). Weakest on Water Impact and Nature & Biodiversity Impact (3/10, 3/10).
9 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.
“Direct emissions (Scope 1) 12,794 … Indirect emissions (Scope 2) (market-based) 11,868”
“In 2023 SmithNephew started two significant on-site solar project installations in China and Malaysia, both systems are now live”
“63% reduction in Scope 1 and 2 GHG emissions from 2019 baseline … Data independently assured by ERM CVS”
“ALLEVYN Dressing cartons use cardboard from Forest Stewardship Council (FSC) certified sources”
“purchased goods and services contributes the most significant proportion … over 83%”
“reduction in our environmental impact (Scope 1 and 2 Greenhouse Gas emissions relative to a 2019 baseline)”
“670,000m3 used vs 672,000m3 during 2023”
“Enabled water conservation through on-site rainwater reuse and focus our manufacturing in low water risk geographies”
“the majority of companies continue to increase their procurement through power purchase agreements … in retail and healthcare not strategically involved in climate policy”
If you believe a source has been misread or a newer version exists, submit a challenge.
Where Smith & Nephew sits among healthcare / pharmaceuticals peers.
Among the 12 major healthcare / pharmaceuticals brands we've scored, Smith & Nephew sits 2nd of 12.
Score history begins —.
As Smith & Nephew's score updates, the trajectory will appear here.
We're backfilling historical scores for FTSE 100 and S&P 100 companies over the coming weeks.
This score is not currently being contested.
Every challenge is published. We'd rather be corrected than wrong — that's the whole point.
No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.
Smith & Nephew is a London-headquartered medical technology company manufacturing wound care, orthopedic, and surgical products. Founded in 1856, it operates globally with ~18,000 employees. The company is a FTSE 100 constituent and significant player in healthcare device manufacturing.
Peer pharmaceutical/healthcare OEM with global manufacturing footprint and ESG disclosure.
View breakdown →Rival healthcare company with comparable size, manufacturing operations, and sustainability reporting scope.
View breakdown →Large FMCG/healthcare manufacturer with extensive supply chain disclosure and nature-related targets.
View breakdown →Global manufacturer with similar water usage scale and advanced circular economy commitments.
View breakdown →Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Readers and institutions support our work. Companies can pay to submit evidence we couldn't find. Neither type of payment changes a score.